Marea Therapeutics

What happens when you build a pipeline that combines cardiometabolic & endocrine diseases? Well, you’ll probably find Marea. Cardioendocrine diseases impact the lives of millions & we are advancing a clinical-stage pipeline to treat them. Learn more at mareatx.com

We leverage precision medicine to pinpoint disease drivers and identify targeted patient populations for more effective treatments. By designing trials around validated biomarkers, we accelerate development to bring life-changing therapies to patients faster.

At Marea, we’re harnessing breakthroughs in human genetics & cutting-edge data science to revolutionize treatment for cardioendocrine diseases. We are developing precise, targeted therapies to address the root cause of dysfunction to deliver better outcomes to those who need them…

This weekend, we presented preclinical data on MAR002 for the treatment of #acromegaly at #ENDO2025. The data strongly support advancing MAR002 into clinical development for acromegaly treatment, and we look forward to staying on track to initiate a Phase 1 First-in-Human study…

We’re excited to announce Shishir Gadam has been appointed as chief technical officer! Shishir brings a remarkable track record of technical leadership across biologics, vaccines, and cell therapies. His deep expertise will be instrumental as we advance our pipeline toward…

Details: mareatx.com/press-releases… We look forward to sharing an update on our preclinical research of MAR002, a potential first-in-class anti-growth hormone receptor antibody, for the treatment of acromegaly at #ENDO2025.

Adipose tissue not only stores energy but also plays a role in regulating the body’s physiology. New research shows adipose dysfunction is linked to many cardioendocrine diseases. We’re exploring smarter treatments to improve adipose tissue function and unlock new possibilities.…

Marea co-founders Josh Lehrer & @ethanjweiss joined @ldtimmerman on The Long Run podcast to share insights into our unique approach to tackling #cardiometabolic diseases and what it takes to build a company around a game-changing idea. Tune in below. timmermanreport.com/2025/05/a-new-…

CDO Rebecca Juliano, Ph.D., will join the 2025 #NLASessions for an encore presentation of our MAR001 Phase 2a data. This ANGPTL4-targeting antibody showed up to a 52.7% reduction in triglycerides and 66.0% reduction in remnant #cholesterol in patients with elevated baseline…

CEO Josh Lehrer & CFO Ian Clements will attend the annual @Jefferies Global Healthcare Conference next week. We look forward to sharing more about our clinical-stage pipeline of novel therapies to address genetically-validated drivers of #cardioendocrine diseases.

We are pleased to announce the appointment of Charmi Turner as SVP, People & Culture. Her human resources expertise in the life sciences industry will be essential in enhancing leadership development and organizational alignment at Marea as we advance the clinical development of…

Following the #EASCongress2025, we’re pleased to share that Phase 2a and preclinical data from our MAR001 program have been published in @TheLancet and @eBioMedicine, respectively. A sincere thank you to the Marea team members, clinical trial investigators and patients who have…

Today, we presented positive data from the Phase 2a clinical trial of MAR001 in a late-breaking oral session at the #EASCongress2025. These data validate the ability of MAR001 to significantly lower remnant cholesterol and triglycerides by inhibiting ANGPTL4. We look forward to…

As Marea grows & evolves, we’re thrilled to move into a new space! Our new office isn’t just a new location; it’s a hub for collaboration, creativity, & #innovation. Designed for the future, it reflects our ambition to push the boundaries of #cardioendocrine diseases. We can’t…

Following our announcement yesterday of our #EASCongress2025 late-breaker presentation for MAR001, our ANGPTL4 inhibitor, Marea Co-founder & CSO @ethanjweiss & CEO Josh Lehrer sat down with @BiotechTVHQ's @bradloncar. Listen below as they break down the approach behind MAR001…

We are pleased to share that two abstracts on our lead program, MAR001, will be presented at the 93rd @society_eas Congress next month. Details: businesswire.com/news/home/2025…

We believe the best work happens in the right environment, where challenge meets support & inspiration, so being named a @SFBusinessTimes & @SVBizJournal #BPTW means so much to us. We're driven by curiosity, fueled by impact, & united in transforming the future of…

Marea Therapeutics leadership will be engaging with the investment community with Needham and @Piper_Sandler. We look forward to connecting with investors and sharing our strategic vision for advancing #cardioendocrine innovation.

We’re excited to be recognized as a 2025 #BestPlacetoWork in the Bay Area by @SFBusinessTimes & @svbizjournal. Tackling cardiometabolic & endocrine disease takes more than cutting-edge science—it takes a team that’s authentic, resilient, audacious, and humble at its core. We’re…

CEO Josh Lehrer will present at @Piper_Sandler's 2nd Annual Virtual Cardio Day, featuring key takeaways from industry leaders to discuss the latest in #cardiovascular research. We look forward to sharing our progress & insights as we continue to drive innovation in…